Stocks analysis

ABBV vs ALB Stock Comparison

Scores Breakdown

Metric ABBV ALB
📈 Growth 26/30 27/30
💰 Profitability 18/20 15/20
🏦 Financial Health 6/20 18/20
💵 Valuation 12/20 14/20
⚠️ Risk (lower is better) 8/10 7/10
Overall Score 64/100 77/100

Side-by-Side Summaries

ABBV Analysis ALB Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

  • Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
  • Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Across eight quarters, ALBEMARLE shows modest revenue growth from about $1.43B in 2024-Q2 to $1.74B in 2026-Q2, a gain of ~22%. Net income evolved from a loss of about -$176.6M to a positive $499.2M in 2026-Q2, with a mid-2025 dip, then a clear recovery into 2026.

💰 Margins & Cash Flow

Gross margin expanded from a negative figure in 2024-Q2 to roughly 35% in 2025-Q1 and remained around the high 30% into 2026. Operating leverage benefited from higher margin production in later quarters. Net cash flow from operating activities, continuing, stayed strong, with $709.997M in 2026-Q2 and positive quarterly cash generation overall. Free cash flow was primarily consumed by investing activities, which were negative but the company still reported a positive overall cash flow in 2026-Q2.

🛡️ Balance Sheet & Liquidity

Total assets of about $15.9B and equity of ~$10.5B support a solid balance sheet. Current assets of roughly $3.9B and current liabilities of $1.89B yield a healthy current ratio around 2.1x. Long-term debt remains moderate at about $1.88B, keeping balance-sheet risk contained.

⚠️ Key Drivers & Risks

  • Drivers: Lithium/alloy battery demand; EV and energy-storage deployment
  • Risks: commodity-price cyclicality; execution/valuation sensitivity to macro conditions